INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 342 filers reported holding INTELLIA THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.72 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,781,833 | -66.7% | 87,977 | -57.1% | 0.00% | -66.7% |
| Q2 2023 | $8,353,335 | +365.0% | 204,839 | +325.0% | 0.00% | +200.0% |
| Q1 2023 | $1,796,451 | -15.6% | 48,201 | -21.0% | 0.00% | 0.0% |
| Q4 2022 | $2,129,092 | +23.0% | 61,023 | +97.3% | 0.00% | 0.0% |
| Q3 2022 | $1,731,000 | -16.5% | 30,931 | -22.8% | 0.00% | 0.0% |
| Q2 2022 | $2,073,000 | -84.6% | 40,050 | -78.3% | 0.00% | -80.0% |
| Q1 2022 | $13,418,000 | -31.5% | 184,647 | +11.5% | 0.01% | -16.7% |
| Q4 2021 | $19,582,000 | -15.4% | 165,614 | -4.0% | 0.01% | -33.3% |
| Q3 2021 | $23,149,000 | -75.7% | 172,561 | -70.7% | 0.01% | -75.7% |
| Q2 2021 | $95,236,000 | +475.5% | 588,199 | +185.3% | 0.04% | +362.5% |
| Q1 2021 | $16,547,000 | -6.1% | 206,177 | -36.4% | 0.01% | -11.1% |
| Q4 2020 | $17,625,000 | +2693.2% | 324,011 | +920.1% | 0.01% | – |
| Q3 2020 | $631,000 | -66.8% | 31,762 | -64.9% | 0.00% | -100.0% |
| Q2 2020 | $1,902,000 | – | 90,478 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 1,216,340 | $62,958,000 | 7.04% |
| Discovery Value Fund | 584,483 | $30,253,000 | 6.33% |
| MPM BioImpact LLC | 299,409 | $15,497,000 | 4.30% |
| ARK Investment Management | 9,514,580 | $439,003,000 | 2.60% |
| Elmwood Wealth Management, Inc. | 67,899 | $3,514,000 | 2.00% |
| Nikko Asset Management Americas, Inc. | 2,781,136 | $141,143,000 | 1.74% |
| Avidity Partners Management LP | 1,125,194 | $58,240,000 | 1.34% |
| Merlin Capital, Inc | 12,174 | $630,000 | 1.26% |
| Atlas Venture Associates IX, LLC | 10,000 | $518,000 | 1.18% |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | 111,440 | $5,768,000 | 1.16% |